IL304544A - Combination therapy of obizezib and ezetimibe for use in statin-intolerant patients suffering from excess fat or mixed lipid deficiency - Google Patents
Combination therapy of obizezib and ezetimibe for use in statin-intolerant patients suffering from excess fat or mixed lipid deficiencyInfo
- Publication number
- IL304544A IL304544A IL304544A IL30454423A IL304544A IL 304544 A IL304544 A IL 304544A IL 304544 A IL304544 A IL 304544A IL 30454423 A IL30454423 A IL 30454423A IL 304544 A IL304544 A IL 304544A
- Authority
- IL
- Israel
- Prior art keywords
- obicetrapib
- ezetimibe
- hyperlipidemia
- combination therapy
- patients suffering
- Prior art date
Links
- 208000032928 Dyslipidaemia Diseases 0.000 title 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title 1
- 229960000815 ezetimibe Drugs 0.000 title 1
- NRWORBQAOQVYBJ-GJZUVCINSA-N obicetrapib Chemical compound N=1C=C(OCCCC(O)=O)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NRWORBQAOQVYBJ-GJZUVCINSA-N 0.000 title 1
- 229950004285 obicetrapib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2021050109 | 2021-02-18 | ||
| PCT/NL2022/050083 WO2022177428A1 (en) | 2021-02-18 | 2022-02-18 | Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304544A true IL304544A (en) | 2023-09-01 |
Family
ID=74844966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304544A IL304544A (en) | 2021-02-18 | 2023-07-18 | Combination therapy of obizezib and ezetimibe for use in statin-intolerant patients suffering from excess fat or mixed lipid deficiency |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240189311A1 (https=) |
| EP (1) | EP4294387A1 (https=) |
| JP (1) | JP2024507810A (https=) |
| KR (1) | KR20230159380A (https=) |
| CN (1) | CN117042770A (https=) |
| AU (1) | AU2022223224A1 (https=) |
| BR (1) | BR112023016682A2 (https=) |
| CA (1) | CA3210033A1 (https=) |
| IL (1) | IL304544A (https=) |
| MX (1) | MX2023009613A (https=) |
| WO (1) | WO2022177428A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2024165395A1 (en) * | 2023-02-07 | 2024-08-15 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025146445A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib and ezetimibe |
| WO2025146262A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146446A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib |
| WO2025147235A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Fixed dose combination composition of obicetrapib and ezetimibe |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| MX369471B (es) * | 2014-02-05 | 2019-11-08 | Dezima Pharma B V | Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares. |
| WO2017023166A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor |
| US12006305B2 (en) * | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| JP2025527686A (ja) * | 2022-08-22 | 2025-08-22 | ニューアムステルダム・ファルマ・ベー・フェー | オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物 |
-
2022
- 2022-02-18 CN CN202280015230.8A patent/CN117042770A/zh active Pending
- 2022-02-18 JP JP2023549866A patent/JP2024507810A/ja active Pending
- 2022-02-18 AU AU2022223224A patent/AU2022223224A1/en active Pending
- 2022-02-18 KR KR1020237028087A patent/KR20230159380A/ko active Pending
- 2022-02-18 CA CA3210033A patent/CA3210033A1/en active Pending
- 2022-02-18 MX MX2023009613A patent/MX2023009613A/es unknown
- 2022-02-18 BR BR112023016682A patent/BR112023016682A2/pt unknown
- 2022-02-18 EP EP22705485.5A patent/EP4294387A1/en active Pending
- 2022-02-18 US US18/277,851 patent/US20240189311A1/en active Pending
- 2022-02-18 WO PCT/NL2022/050083 patent/WO2022177428A1/en not_active Ceased
-
2023
- 2023-07-18 IL IL304544A patent/IL304544A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024507810A (ja) | 2024-02-21 |
| AU2022223224A1 (en) | 2023-08-24 |
| CN117042770A (zh) | 2023-11-10 |
| MX2023009613A (es) | 2023-11-09 |
| WO2022177428A1 (en) | 2022-08-25 |
| BR112023016682A2 (pt) | 2023-11-14 |
| EP4294387A1 (en) | 2023-12-27 |
| KR20230159380A (ko) | 2023-11-21 |
| US20240189311A1 (en) | 2024-06-13 |
| CA3210033A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304544A (en) | Combination therapy of obizezib and ezetimibe for use in statin-intolerant patients suffering from excess fat or mixed lipid deficiency | |
| IL299167A (en) | Compositions and methods for treating patients with gene therapy | |
| IL318196A (en) | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES | |
| ZA202208630B (en) | Use of pharmaceutical composition for preventing and treating novel coronavirus pneumonia | |
| EP4119156A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| IL312583A (en) | A preparation for the treatment and prevention of COVID-19 | |
| CA3265606A1 (en) | OBITECRAPIB AND EZETIMIBE POLYTHERAPY AND FIXED-DOSE PHARMACEUTICAL COMPOSITIONS | |
| HK40105287A (en) | Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia | |
| IL311999A (en) | New modulators of EHMT1 and EHMT2 and their therapeutic use | |
| EP4119157A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| IL320242A (en) | Compounds and their use for the treatment of hemoglobinopathy | |
| IL318680A (en) | Pharmaceutical preparations and their uses for the treatment of glioma | |
| EP4349339A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER AND ITS USE | |
| AU2021381054A9 (en) | Pharmaceutical compositions for use in the management and treatment of pain | |
| EP4551220A4 (en) | Pharmaceutical compositions and methods for treating insomnia | |
| GB202208022D0 (en) | Therapeutic compounds and compositions | |
| IL320820A (en) | Therapeutic combinations of captopril and ventocalix | |
| HK40127165A (zh) | 奥比塞曲匹与依折麦布组合治疗和固定剂量药物组合物 | |
| CA3277833A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3264563A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3264839A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3265629A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3264914A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3264878A1 (en) | Medicament for treatment and/or prevention of cancer |